Qingchun Zhao

22PUBLICATIONS
18CO-AUTHORS
Molecular targetsAutoimmunityMedical bacteriologyMetabolic medicineCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Mar 12, 2026
Structure-Based Discovery of HS34: A Highly Selective and Orally Bioavailable CDK9 Inhibitor for Triple-Negative Breast Cancer.

Yaoguang Huang, Wenwu Liu, Xiaoyu Shi

|Mar 09, 2026
ZRMQ-22, a novel DYRK1A inhibitor, attenuates neuroinflammation and cognitive impairments in LPS-induced mice: a potential strategy for Alzheimer's disease.

Mengyu Ren, Huanhua Chen, Zhenshu Li

|Mar 06, 2026
Novel β-Carboline Derivative ZLWH-67 Exerts Potent Anti-MRSA Activity through Multiple Mechanisms.

Jiacheng Zhuang, Junjie Lin, Wenjie Liu

|Feb 27, 2026
Multi-Targeted Therapeutic Mechanisms of Huangqi Guizhi Wuwu Decoction Against Rheumatoid Arthritis: An Integrated Approach Combining Serum Pharmacochemistry, Network Pharmacology, Metabolomics, and Experimental Validation.

Zihua Xu, Zhenshu Li, Jiameng Qu

|Nov 15, 2025
Fluorocyclopropyl-Containing Tacrine Derivatives as Potent and Selective Dual CDK2/CDK9 Inhibitors for the Treatment of Colorectal Cancer.

Limeng Wu, Wenjie Liu, Xinyue Ning

|Oct 24, 2025
The role of neutrophils, red blood cells, and platelets in the pathology of Alzheimer's disease.

Yan Xu, Xiangdong Li, Qingchun Zhao

Pageof 4

Frequent Collaborators

3 joint publications

Wenwu Liu

2 joint publications

Xiangbo Xu

2 joint publications

Zihua Xu

1 joint publications

Han Chen